ArticleInternational journal of rheumatic diseases2019
Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial.
Article in International journal of rheumatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Comparison of Efficacy and Safety of Different Medication Protocols in Patients with Immunoglobulin G4-Related Disease Based on Follow-up Time: A Systematic Review and Network Meta-analysis.Archives of rheumatology · 2026Article
- Recurrent IgG4-related Tubulointerstitial Nephritis Successfully Treated With Obinutuzumab: A Case Report and Literature Review.Kidney medicine · 2026Article
- Correlations between IgG4-related disease, autoimmune pancreatitis, and allergic diseases.Frontiers in immunology · 2026Review
- IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort.Clinical rheumatology · 2025Article
- Omics in IgG4-related disease.Chinese medical journal · 2025Review
- Comparison of the effect of iguratimod and hydroxychloroquine on regulatory B cells in the treatment of primary Sjögren's syndrome.Frontiers in medicine · 2025Article
- Current and future advances in practice: IgG4-related disease.Rheumatology advances in practice · 2024Review
- Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study.Clinical rheumatology · 2023Article
- Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.Frontiers in immunology · 2023Review
- IgG4-Related Disease Manifested as Cutaneous Plasmacytosis: A Case Report.Clinical, cosmetic and investigational dermatology · 2023Article
- IgG4-related digestive diseases: diagnosis and treatment.Frontiers in immunology · 2023Review
- The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin G4-related disease.Clinical & translational immunology · 2023Review
- Article
- Clinical features and treatment efficacy for IgG4-related thyroiditis.Orphanet journal of rare diseases · 2021Article
- Differential Tissue Metabolic Signatures in IgG4-Related Ophthalmic Disease and Orbital Mucosa-Associated Lymphoid Tissue Lymphoma.Investigative ophthalmology & visual science · 2021Article
- Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease.Frontiers in immunology · 2021Article
- Improved clinical outcomes of tocilizumabTherapeutic advances in chronic disease · 2021Article
- Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.Clinical rheumatology · 2020Article
- Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial.International journal of rheumatic diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Funding
Abstract
aimThe purpose of this study is to evaluate the therapeutic efficacy and safety of iguratimod plus corticosteroid as bridge therapy in the treatment of mild immunoglobulin G4-related disease (IgG4-RD).
methodsNewly diagnosed IgG4-RD patients, without internal organ involvement were enrolled. Patients were given one dose of diprospan, intramuscular injection, and iguratimod, 25 mg, twice daily, for 24 weeks and were followed up at 0, 12 and 24 weeks. Follow-up indexes included IgG4-RD responder index (IgG4-RD RI), serology and imaging, plasma cytokines and adverse drug effect. Flow cytometry was performed for T, B cell subsets and plasma was collected for liquid chromatography mass spectrometry (LC-MS)-based metabolomic profiling and data processing.
resultsThirty patients were enrolled. At week 24, 9 (30.0%) patients achieved complete response, 17 (56.7%) patients with partial response, and 4 (13.3%) patients had no response to treatment. IgG4-RD RI, serum IgG and IgG4 levels decreased significantly at weeks 12 and 24 after treatment, as well as CD3+ CD8+ T cells, plasmablast/plasma cells and memory B cells. The LC-MS based plasma metabolomic profiles revealed significant changes between untreated patients and healthy donors, which became much similar to normal states after treatment.
conclusionIguratimod plus corticosteroid as bridge therapy is effective for the treatment of mild IgG4-RD, it can improve the clinical symptoms, reduce serum IgG and IgG4 levels, especially plasmablasts/plasma cells and memory B cells. In addition, the metabolite profiling became similar to normal controls after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.